SLC16A1 and Alzheimer disease: A study on the SCFAs in vivo showed that the treatment of SCEP induced the increased expression of MCT-1 in both the colon and the cortex, resulting in the re-distribution and increased levels of SCFAs in the feces, blood, and brain of AD mice, which may help to mediate the neuroprotective effect of SCEP.